Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind parallel-dose multicenter trial of Fufang Rongzhu granules in elderly functional constipation
CTR20242864Phase 3Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fufang Rongzhu granules in functional constipation (FC) (2 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoint: Responder rate for complete spontaneous bowel movements during 8-week treatment period. Started Nov 2024; status: completed.
02
Drugs
Fufang Rongzhu granules
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on CTR20242864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242864.